Successful re-treatment of hepatitis C virus in patients coinfected with HIV Who relapsed after 12 weeks of ledipasvir/sofosbuvir

Curtis Cooper; Susanna Naggie; Michael Saag; Jenny C. Yang; Luisa M. Stamm; Hadas Dvory-Sobol; Lingling Han; Phillip S. Pang; John G. McHutchison; Douglas Dieterich; Mark Sulkowski

doi:10.1093/cid/ciw349

Successful re-treatment of hepatitis C virus in patients coinfected with HIV Who relapsed after 12 weeks of ledipasvir/sofosbuvir

Curtis Cooper, Susanna Naggie, Michael Saag, Jenny C. Yang, Luisa M. Stamm, Hadas Dvory-Sobol, Lingling Han, Phillip S. Pang, John G. McHutchison, Douglas Dieterich, Mark Sulkowski

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 weeks of treatment with ledipasvir/sofosbuvir. Eight of 9 (89%) achieved sustained virologic response 12 weeks after the end of treatment. One patient relapsed at posttreatment week 4. These results suggest an effective salvage therapy for patients for whom direct-acting antiviral treatment has failed. Clinical Trials Registration. NCT02073656.

Original language	English
Pages (from-to)	528-531
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	63
Issue number	4
DOIs	https://doi.org/10.1093/cid/ciw349
State	Published - 15 Aug 2016

Keywords

Direct-acting antiviral agents
HCV NS5B polymerase inhibitor
HCV/HIV coinfection
NS5A resistance
Re-treatment

Access to Document

10.1093/cid/ciw349

Cite this

Cooper, C., Naggie, S., Saag, M., Yang, J. C., Stamm, L. M., Dvory-Sobol, H., Han, L., Pang, P. S., McHutchison, J. G., Dieterich, D., & Sulkowski, M. (2016). Successful re-treatment of hepatitis C virus in patients coinfected with HIV Who relapsed after 12 weeks of ledipasvir/sofosbuvir. Clinical Infectious Diseases, 63(4), 528-531. https://doi.org/10.1093/cid/ciw349

@article{a026d05232b4417da8ab3590e00e079b,

title = "Successful re-treatment of hepatitis C virus in patients coinfected with HIV Who relapsed after 12 weeks of ledipasvir/sofosbuvir",

abstract = "We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 weeks of treatment with ledipasvir/sofosbuvir. Eight of 9 (89%) achieved sustained virologic response 12 weeks after the end of treatment. One patient relapsed at posttreatment week 4. These results suggest an effective salvage therapy for patients for whom direct-acting antiviral treatment has failed. Clinical Trials Registration. NCT02073656.",

keywords = "Direct-acting antiviral agents, HCV NS5B polymerase inhibitor, HCV/HIV coinfection, NS5A resistance, Re-treatment",

author = "Curtis Cooper and Susanna Naggie and Michael Saag and Yang, {Jenny C.} and Stamm, {Luisa M.} and Hadas Dvory-Sobol and Lingling Han and Pang, {Phillip S.} and McHutchison, {John G.} and Douglas Dieterich and Mark Sulkowski",

year = "2016",

month = aug,

day = "15",

doi = "10.1093/cid/ciw349",

language = "English",

volume = "63",

pages = "528--531",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Successful re-treatment of hepatitis C virus in patients coinfected with HIV Who relapsed after 12 weeks of ledipasvir/sofosbuvir

AU - Cooper, Curtis

AU - Naggie, Susanna

AU - Saag, Michael

AU - Yang, Jenny C.

AU - Stamm, Luisa M.

AU - Dvory-Sobol, Hadas

AU - Han, Lingling

AU - Pang, Phillip S.

AU - McHutchison, John G.

AU - Dieterich, Douglas

AU - Sulkowski, Mark

PY - 2016/8/15

Y1 - 2016/8/15

N2 - We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 weeks of treatment with ledipasvir/sofosbuvir. Eight of 9 (89%) achieved sustained virologic response 12 weeks after the end of treatment. One patient relapsed at posttreatment week 4. These results suggest an effective salvage therapy for patients for whom direct-acting antiviral treatment has failed. Clinical Trials Registration. NCT02073656.

AB - We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 weeks of treatment with ledipasvir/sofosbuvir. Eight of 9 (89%) achieved sustained virologic response 12 weeks after the end of treatment. One patient relapsed at posttreatment week 4. These results suggest an effective salvage therapy for patients for whom direct-acting antiviral treatment has failed. Clinical Trials Registration. NCT02073656.

KW - Direct-acting antiviral agents

KW - HCV NS5B polymerase inhibitor

KW - HCV/HIV coinfection

KW - NS5A resistance

KW - Re-treatment

UR - http://www.scopus.com/inward/record.url?scp=84982107437&partnerID=8YFLogxK

U2 - 10.1093/cid/ciw349

DO - 10.1093/cid/ciw349

M3 - Article

C2 - 27225242

AN - SCOPUS:84982107437

SN - 1058-4838

VL - 63

SP - 528

EP - 531

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 4

ER -

Successful re-treatment of hepatitis C virus in patients coinfected with HIV Who relapsed after 12 weeks of ledipasvir/sofosbuvir

Abstract

Keywords

Access to Document

Fingerprint

Cite this